TB-500 and Thymosin Beta-4: Separating the Two
Much of what is written about TB-500 borrows research on thymosin beta-4, a different, much larger molecule. FDA could not find a single human study of TB-500 itself. Here is how to tell them apart.
Search for TB-500 and you will be told, again and again, that it is thymosin beta-4. It is not. One is a 43-amino-acid protein your body makes in almost every cell and that has been tested in human clinical trials. The other is a seven-amino-acid synthetic fragment that FDA, in 2026, could not find a single human study of. Mixing them up is how a thin evidence base starts to look thick.
The short version
- Thymosin beta-4 (Tβ4) is a naturally occurring 43-amino-acid protein. Investigational eye-drop versions have been through human trials, with mixed results. It is not FDA-approved for any use.
- TB-500, as FDA defines it, is a synthetic seven-amino-acid fragment of Tβ4. FDA's 2026 review found no human studies of TB-500 for any condition.
- Much of what is written about "TB-500" borrows research done on the full Tβ4 protein, often in animals.
- In July 2026 an FDA advisory committee voted 8–6, with one abstention, to recommend adding TB-500 to the 503A bulks list. That is non-binding, and it still could not lawfully be compounded from bulk as of mid-September 2026.
- Both Tβ4 and its derivatives, including TB-500, are prohibited at all times under the WADA Code.
What is thymosin beta-4?
Thymosin beta-4 is a small protein made of 43 amino acids. Despite the name, which comes from its original isolation from thymus tissue, it is found in most cells in the body and is particularly abundant in platelets and white blood cells.
Its best-understood job is housekeeping. Tβ4 binds to actin, the protein cells use to build their internal scaffolding and to move. By holding individual actin units in reserve, it helps regulate when and where that scaffolding gets built. Because cell movement matters for wound repair, blood vessel formation and inflammation, researchers have spent decades asking whether extra Tβ4 could help tissues heal.
Some of that work drew real scientific attention. A 2004 paper in Nature by Bock-Marquette and colleagues reported that Tβ4 promoted survival and migration of heart muscle cells and improved heart function in mice after an induced heart attack. That was a mouse study, and it has not translated into an approved heart treatment, but it helps explain why the molecule has a following.
What is TB-500?
This is where things get muddy, and the muddiness is not your fault.
In its 2026 briefing for the Pharmacy Compounding Advisory Committee, FDA defined TB-500 as a synthetic peptide of seven amino acids, acetylated at one end, corresponding to positions 17 to 23 of thymosin beta-4. That short stretch (often written LKKTETQ) is the region of Tβ4 involved in binding actin. The idea behind it is that this fragment might carry some of the parent protein's activity in a smaller, cheaper molecule.
Online, though, "TB-500" is used loosely. Some sellers use the name for the seven-amino-acid fragment, some for the full 43-amino-acid protein, and some product pages use the two names interchangeably. Since research-use vials are not verified by any regulator, a label saying TB-500 tells you very little about which molecule, if either, is inside.
Worth knowing
A fragment is not a miniature version of the whole. Proteins work through their overall shape and several binding regions at once. FDA's TB-500 briefing noted one laboratory study in which the TB-500 fragment did not promote wound closure in fibroblast cells, the opposite of what you would expect if it simply mimicked the full protein. That is a single in-vitro result, but it illustrates why you cannot borrow Tβ4 data and assume it applies to TB-500.
What has been studied in humans?
Thymosin beta-4 (the full protein)
The most substantial human research on Tβ4 involves an investigational eye-drop formulation called RGN-259, studied for neurotrophic keratopathy, a condition in which the cornea loses nerve supply and struggles to heal.
- SEER-1. A randomized, placebo-controlled Phase 3 trial with 18 patients, published in the International Journal of Molecular Sciences. Complete corneal healing at four weeks occurred in 6 of 10 people on RGN-259 and 1 of 8 on placebo. The authors described this as a strong trend; with numbers that small, it fell short of establishing effectiveness, though differences at later time points were reported as statistically significant.
- SEER-3. A larger European Phase 3 trial announced in June 2025 that it had missed its primary endpoint of complete corneal healing at four weeks, which the sponsor attributed to a stronger-than-expected placebo response. At that time, a US Phase 3 trial (SEER-2) was reported as ongoing.
Notice what this research is: a specific formulation, applied to the eye, in a specific rare disease, under trial conditions. It is exactly how a peptide should be studied, and even so, the results so far are mixed. None of it tells you anything about injecting Tβ4 under the skin for a sore shoulder.
TB-500 (the fragment)
FDA's reviewers were blunt. Neither the nomination nor FDA's own literature search found any information on TB-500 being given to patients to treat any disease or condition. The briefing also noted the absence of standard nonclinical safety studies: no acute or repeat-dose toxicity, genotoxicity, reproductive or carcinogenicity data.
You will sometimes see a 2021 knee-pain report cited as TB-500 evidence. That retrospective case series (Lee and Padgett, Alternative Therapies in Health and Medicine) primarily involved BPC-157, with some patients also receiving thymosin beta-4. It had no control group and cannot tell you what either substance contributed. We discuss it in our article on BPC-157's evidence and legal status.
Is TB-500 safe?
Without human studies, there is no basis for calling it safe or unsafe. What FDA's briefing did set out were specific concerns:
- Immunogenicity. Peptides injected into muscle or under the skin can trigger immune responses, a risk FDA said may be amplified by aggregation and peptide-related impurities.
- Quality. Certificates of analysis FDA reviewed lacked specifications for bacterial endotoxins and did not fully characterize impurities. For an injectable, endotoxin and sterility are not details.
- No toxicology. FDA found none of the standard animal safety studies that normally come before first human use.
There is also a theoretical question about the parent molecule. Tβ4 is involved in cell migration and blood vessel formation, and laboratory research has linked higher Tβ4 expression to tumor cell migration in some cancers, including a 2003 laboratory and mouse study in the Journal of the National Cancer Institute (Cha, Jeong and Kleinman). The picture is not uniform; other research has associated Tβ4 with tumor-suppressive effects in multiple myeloma. None of this shows that TB-500 injections cause cancer. It is a reason a careful clinician would be especially cautious in anyone with a current or past malignancy.
Be careful here
Nearly all TB-500 sold to consumers is a "research use only, not for human consumption" vial. That places it entirely outside the pharmacy system: no verified identity, purity, concentration or sterility, and no one accountable if something goes wrong. Injecting an unverified powder you mixed yourself is a genuine infection and contamination risk, whatever the molecule does. Our article on the research peptide grey market explains why.
Where TB-500 stands legally
Neither TB-500 nor thymosin beta-4 is an FDA-approved drug. RGN-259 remains investigational.
On compounding, TB-500 followed the same path as BPC-157 in 2026. After HHS Secretary Robert F. Kennedy Jr. announced a plan on February 27 to revisit FDA restrictions on certain peptides, FDA removed a number of peptides from Category 2 in April so they could be reviewed. Removal from Category 2 was not permission to compound. On July 23, the Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend adding TB-500 (free base and acetate) to the 503A bulks list for wound healing. FDA's reviewers had recommended against it, citing the lack of any evidence of effectiveness, insufficient characterization and the availability of FDA-approved wound-care treatments.
The vote is non-binding. FDA would need to complete notice-and-comment rulemaking before TB-500 could lawfully be compounded from bulk, and legal analyses in August 2026 concluded it still could not be. No final rule had been reported as of this writing. Our full explainer on the July 2026 FDA peptide vote covers what comes next. Rules change, so verify the current position with FDA.
Athletes: this one is clear
The WADA Prohibited List names "thymosin-β4 and its derivatives, e.g. TB-500" under class S2 (peptide hormones, growth factors, related substances and mimetics). Substances in S2 are prohibited at all times, in and out of competition. No compounding decision by FDA changes that. If you are subject to drug testing, see our guide to peptides and drug testing.
What to do if you are considering TB-500
Most people asking about TB-500 have an injury, usually a tendon, ligament or muscle problem that has not healed as fast as they want. That problem is worth taking seriously on its own terms. The evidence-backed options for soft-tissue injuries, including structured loading programs, physical therapy and, where appropriate, imaging and specialist review, are covered in peptides for joint and tendon injuries: what orthopedic evidence exists.
If a provider is offering TB-500, a few questions are worth asking:
- Is this the seven-amino-acid fragment or full-length thymosin beta-4, and how do you know?
- Which pharmacy prepares it, and what is its legal basis for compounding it today?
- What human evidence supports using it for my injury?
- Is it being combined with other peptides, and if so, why? (Combinations multiply the unknowns; see why peptide stacks are a red flag.)
- What would you monitor, and what would make you stop?
A provider who answers all five clearly, including "the human evidence is essentially nonexistent," is being straight with you. One who cannot is telling you something too.
If you would rather talk it through with a licensed clinician who will review your history, explain where TB-500 and thymosin beta-4 stand on the day you ask, and suggest options with better evidence where they exist, our peptide therapy consultations are designed for exactly that. A consultation does not guarantee a prescription, and sometimes the honest answer is that a peptide is not the right tool.
Common questions
Is TB-500 the same as thymosin beta-4?
No. FDA defines TB-500 as a synthetic seven-amino-acid fragment corresponding to positions 17–23 of thymosin beta-4, which is a 43-amino-acid protein. Some sellers use the names interchangeably, which is part of the confusion.
Is TB-500 FDA-approved?
No. Neither TB-500 nor thymosin beta-4 is approved for any use. A July 2026 advisory committee vote concerned compounding, not approval, and was non-binding.
Has TB-500 been tested in humans?
FDA's 2026 review found no published information on TB-500 being given to patients for any condition. Human trials exist for the full thymosin beta-4 protein as investigational eye drops, with mixed results.
Is TB-500 banned in sports?
Yes. Thymosin beta-4 and its derivatives, including TB-500, are listed under S2 of the WADA Prohibited List and are prohibited at all times.
Talk to a licensed clinician
Reading about a treatment is not the same as knowing whether it fits your history. A consultation is a conversation about your own situation — not a sales call, and not a promise of any outcome.
Book a consultation
